Mapping CMC for ACTD: Placing Specs, Validation, and Stability When You Start from CTD Why CMC Mapping Matters: “Same Science, Different Wrapper” and the Risk of Silent Drift Quality/CMC is the backbone of any dossier, and it travels surprisingly well across formats—if you place it correctly. The ICH CTD organizes quality in Module 3 as 3.2.S (Drug Substance) and 3.2.P (Drug Product) with familiar sub-sections for pharmaceutical development, manufacturing, controls, validation, packaging, and stability. The ACTD quality section carries the same scientific intent but can present different headings and granularity expectations, especially for administrative attachments and country add-ons. Teams…

CTD Module 3 (CMC) Writing: US-Ready Quality Sections with Examples & Templates Writing CTD Module 3 for US Review: Practical CMC Structure, Examples, and Templates Why Module 3 Matters: Turning CMC Know-How into a Reviewable, Defensible Story CTD Module 3 is where your manufacturing science becomes an approvable quality narrative. It must do more than list processes and test results—it should explain how your control strategy assures consistent product performance and why your specifications are clinically and technically justified. For US reviewers, the strongest dossiers make the decision path visible: what the product is, how it is made and controlled,…

DMF Referencing in ANDA: Type II/III/IV/V — LOA Mechanics, CTD Placement, and Risk Controls Using DMFs in US ANDAs: Types, LOA Mechanics, CTD Placement, and Practical Pitfalls Why DMFs Matter in ANDAs: Speed, Confidentiality, and Reviewer Confidence For most Abbreviated New Drug Applications (ANDAs), key parts of the quality package rely on third-party know-how: drug substance synthesis and control, container–closure barriers, novel excipients, coatings, or specialized processing aids. The Drug Master File (DMF) system allows those owners to confidentially submit proprietary data directly to the U.S. Food & Drug Administration (FDA), while the ANDA cites that data by reference through…

Module 3 Documentation Explained: Ultimate Guide to CMC Quality Dossier Compliance Mastering Module 3 Documentation: Compliance-Ready Guide for Global Regulatory Submissions Introduction to Module 3 Documentation and Its Importance Module 3 of the Common Technical Document (CTD) is the quality section of regulatory submissions that details the chemistry, manufacturing, and controls (CMC) information for a medicinal product. It provides regulators such as the FDA, EMA, CDSCO, and PMDA with comprehensive information on drug substance and drug product development, manufacturing processes, quality controls, and stability data. Module 3 is critical because it ensures that pharmaceutical products are consistently manufactured to meet…

CTD and eCTD Compilation Guide: Best Practices for Regulatory Dossier Submission Mastering CTD and eCTD Compilation: Compliance-Driven Roadmap for Global Submissions Introduction to CTD/eCTD Compilation and Its Importance The Common Technical Document (CTD) and its electronic counterpart, the eCTD, are the cornerstone of regulatory submissions worldwide. Developed by the International Council for Harmonisation (ICH), the CTD format was created to harmonize regulatory dossier submissions across major markets including the U.S. FDA, EMA, Health Canada, PMDA (Japan), and CDSCO (India). The eCTD adds electronic granularity, standardizing structure, navigation, and life-cycle management through XML backbones. For regulatory professionals, CTD/eCTD compilation is not…